Navigating the Regulatory Landscape of Stem Cell Therapies

This chapter explores the intricacies of placental-derived tissues and the regulatory frameworks for stem cell therapies in the U.S. It highlights the distinctions between minimally manipulated tissues and more processed options, alongside the FDA's cautious stance on biotechnologies and the implications for innovation versus safety in healthcare.